PARTNERSHIPS FOR AFRICAN VACCINE MANUFACTURING (PAVM)
‘FROM ASPIRATION TO ACTION’

PROGRESS MADE SO FAR ON IMPLEMENTING THE PARTNERSHIPS FOR VACCINE MANUFACTURING IN AFRICA

Co-convened by
Africa Centers for Disease Control and Prevention (Africa CDC)
African Medicines Agency (AMA)
African Union Development Agency NEPAD (AU-NEPAD)
and Continental Free Trade Area (CFTA)

06 December – 07 December 2021
10.00 AM - 07.00 PM (GMT+2)
Kigali Serena Hotel, Rwanda

CONCEPT NOTE
1. CONTEXT

12-13 April 2021 African Vaccine Manufacturing Summit

The African Union Commission (AUC) and Africa Centres for Disease Control (Africa CDC) hosted a two-day high-level Summit under the theme “Expanding Africa’s Vaccine Manufacturing for Health Security: Building back better, bolder and bigger.” Amongst the continental leadership in attendance were:

- H.E Moussa Faki Mahamat, Chairperson, African Union Commission;
- H.E Félix Antoine Tshisekedi Tshilombo, Chairperson, African Union, President, Democratic Republic of the Congo;
- H.E Cyril Matamela Ramaphosa, African Union Champion for COVID-19 and President, South Africa and
- H.E Paul Kagame, President, Republic of Rwanda and Chairperson, AUDA-NEPAD.

Over 40,000 people attended via Zoom, YouTube, and Facebook, hearing from more than 70 expert panelists. Major outcomes arising from the high-level Summit were:

1. A commitment to developing a detailed “Framework for Action” with key milestones on the way to reaching 60% local manufacturing of Africa’s routine vaccine needs by 2040
2. The launch of the Partnerships for African Vaccine Manufacturing (PAVM)
3. The live, virtual signing of two Memorandums of Understanding (MoUs) between the African Union and CEPI, and Afreximbank and the Africa Finance Corporation.

You can find the post-summit communique by clicking on the following link – communique

2. PROGRESS IN ESTABLISHING PAVM

The 39th Ordinary Session of the African Union’s Executive Council decision EX.CL/Dec. 1129 (XXXIX) recognized PAVM as the coordinating mechanism and its leadership of the development of a continental vaccine manufacturing strategy and a framework for action.

The four core mandates of the PAVM are to:

a. Steward a continental strategy that maintains scale and cost-competitiveness of local manufacturing and promotes equity and security for all
b. Support partnerships to create a conducive business environment that will encourage the emergence of a thriving manufacturing base
c. Play intermediation and partner role between Member States and the global community of supporters on an as-needed basis
d. Communicate updates and serve as the central source of information for Africa vaccine manufacturing
e. The PAVM is now an effective entity that has started to articulate a detailed strategy (“Framework for Action”) for the years to come and, at the same time, deliver on these core mandates. It thus is and will continue to be at the Centre of the efforts to develop localized vaccine manufacturing in Africa, supporting all stakeholders – AU Member States, financiers, and manufacturers.
Progress since the 12-13th April 2021 Vaccine Manufacturing Summit

1. As of 6th October 17 AU member states have ratified and deposited the instruments at the AU Commission so that the **African Medicines Agency (AMA)** can now finally be launched and start playing a critical role on the continent to strengthen pharmaceutical regulation. It is hoped that more countries will sign up and ratify the AMA Treaty will provide a platform for the coordination and strengthening of ongoing medicines regulatory harmonization initiatives across the continent including in the vaccine manufacturing process. It plans to ensure optimal use of scarce resources by pooling expertise, capacities and strengthening existing networks. The AMA will also offer guidance, in addition to complementing and enhancing the harmonization efforts around vaccine manufacturing ecosystem in Africa.

Since the launch of PAVM, several countries have made remarkable progress:

1. **Algeria**: Launched the local production of Sinovac COVID-19 vaccine (Vero Cell) – CoronaVac.
2. **Egypt**: Signed two agreements between Holding Company for Biological Products and Vaccines (VACSERA) and Sinovac for COVID-19 vaccine manufacturing in the country.
3. **Morocco**: Signed MOU with the Swedish company “Recipharm” to establish and scale-up COVID-19 vaccine manufacturing capacity.
4. **Rwanda** and **Senegal** signed MOU with BioNTech to establish local mRNA vaccine production plants in Africa.
5. **South Africa**: The consortium to establish an **mRNA technology transfer hub in South Africa** to boost vaccine production on the continent brings together the Medicines Patent Pool (MPP), the World Health Organization (WHO), Afrigen Biologics Limited, the Biologicals and Vaccines Institute of Southern Africa (Biovac) and the South African Medical Research Council (SAMRC) and Africa CDC.
6. Establishment of a **vaccine industry talent development program** in partnership with MasterCard Foundation.
7. Coordinated development of local manufacturing capacity on the continent in partnership with the Team Europe Initiative on manufacturing and access to medicines, vaccines and health technologies is considered in different countries.

**Because countries are on an accelerated path, the Africa CDC, AMA and CFTA will be convening a high-level stakeholder’s engagement meeting to prepare AU Member States.**

**OBJECTIVES**

i. Update on progress made so far on the Partnerships for African Vaccine Manufacturing in Africa

ii. Agree on an AU-endorsed approach to facilitate regulatory approval of vaccines produced in Africa

iii. Discuss critical market shaping needs once African countries produce vaccines

iv. Build on the momentum of vaccine manufacture hubs and pilot a drug API-final drug product Hub program
EXPECTED OUTCOMES

1. Align on the recommendation for AU regulatory approach including how to strengthen AMA. AMA has successfully reach the ratification threshold with 15 countries signing.

2. Align on the recommendations for a pooled procurement mechanism for vaccine manufacturing industry in Africa.

3. Provide insights into the program that has been developed in each PAVM workstream.

4. A soft launch of the Framework For Action

5. Reach the required number of ratifications to bring the AMA Treaty into Force.

PARTICIPANTS

Approximately 1000 participants are expected to attend virtually and/or in-person. These are mainly:

- Chairperson of the African Union
- Bureau of Heads of State and Government
- Chairperson of the African Union Commission
- Commissioner for Health, Humanitarian Affairs and Social Development
- Commissioner for Economic Affairs
- AU Ministers of Health
- AU Ministers of Finance
- AU Ministers of Industry
- Africa CDC
- CFTA - Continental Free Trade Area
- European Commission (Team Europe)
- AU Special Envoys for COVID-19 Response
- AU COVID-19 Commission
- United Nations Children’s Fund
- United Nations Development Programme
- World Health Organization
- World Trade Organization
- World Food Programme
- United States Agency for International Development
- United States Centres for Disease Control and Prevention
- European Centres for Disease Control and Prevention
- European Investment Bank
- United States National Institute of Health
- Gavi, the Vaccine Alliance
- Coalition for Epidemic Preparedness Innovations
- The World Bank Group
- Afreximbank
- Africa Development Bank
• African banks and financial institutions
• Bill and Melinda Gates Foundation
• Susan Buffet Foundation
• MasterCard Foundation
• Tony Blair Institute
• Pharmaceutical manufacturers
• Non-pharmaceutical manufacturers
• Business Leaders/Philanthropists
• Representatives of civil society and academia

DATE AND TIME

Monday, 6th December 2021 & Tuesday 7th December 2021
10.00 AM - 7.00PM (GMT+2)

Register in advance for the stakeholder engagement meeting:

https://zoom.us/meeting/register/tJYrdeipqjgsGdYBhximbAEqqODeA3Bp0PQH

After registering, you will receive a confirmation e-mail containing information about joining the meeting.

FOR INQUIRIES PLEASE CONTACT

1. Dr Nicaise Ndemi, Head Science Office, NicaiseN@africa-union.org
2. Dr Chrys Promesse Kaniki, Public Health Analyst, KanikiC@africa-union.org
3. Ms Ezinne Victoria Chinemerem Onwuekwe, Vaccine Coordinator, OnwuekweE@africa-union.org